Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug CIT-013 tested for safety in small human trial

NCT ID NCT07499908

Not yet recruiting Knowledge-focused Sponsor: Citryll BV Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial will test the safety and tolerability of a drug called CIT-013 in 10 healthy adults. Participants receive either CIT-013 or a placebo by injection under the skin. The study is double-blind, meaning neither participants nor researchers know who gets the real drug. Since this is an early-stage trial in healthy people, it does not aim to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CIT-013

What could go wrong

This is a very early phase 1 trial with only 10 healthy volunteers, so it cannot yet show any treatment effect. The main goal is safety, not efficacy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ICON

    Groningen, Netherlands

    Contact